Still using antibacterial soap? Stop. Just stop. Another study finds no greater reduction of bacteria vs plain soap http://t.co/kmMXYm5Qhi
— sharon begley (@sxbegle) September 17, 2015
$LLY EMPA-REG data out in NEJM:
http://t.co/JBRkflqSjQ
HR=0.86, p=0.04 weaker than ppl expected after top-line? pic.twitter.com/daDQFwq6jo
— Andy Biotech (@AndyBiotech) September 17, 2015
The seminal @sciencemagazine paper from Lasker awardee Jim Allison that started #cancer #immunotherapy juggernaut http://t.co/l32mw8OqLk
— Anirban Maitra (@Aiims1742) September 8, 2015
when scientific hypotheses find confirmation from diverse sources you best pay heed
I give you IDO1 and antibodies: http://t.co/Nf157scGik
— Paul D. Rennert (@PDRennert) September 4, 2015
"I work in immuno-oncology."
"What's that?"
"Here, read this..."
http://t.co/4qD7VTsiPb
(Nice job via Drew Pardoll @HopkinsMedicine )
— David Miller (@AlpineBV_Miller) September 1, 2015
NEJM: Not exploiting max potential of statins may have overestimated PCSK9i benefit
http://t.co/zsyjkEeJAd
Relevant to $ESPR P3/CVOT design
— Andy Biotech (@AndyBiotech) August 20, 2015
On tumor heterogeneity http://t.co/xLw69WSoiV @NatureMedicine one of #cancer's greatest challenges for effective Rx pic.twitter.com/0Drp6vxXwY
— Eric Topol (@EricTopol) August 6, 2015
Kind of cool: a PRECLINICAL Multicenter Randomized Control Trial. Evaluated anti-CD49d for acute brain ischemia.
http://t.co/z2Ti1PqOty
— Dan Marks (@Festivus159) August 6, 2015
RT @EricTopol: The "bad luck" #cancer story revisited, w/ a much better explanation http://t.co/zRGNLRhGsS @NEJM pic.twitter.com/nmkzNDe9jH
— Dale Yuzuki (@DaleYuzuki) July 30, 2015
RSS Feed
